HIV drug resistance and treatment success study
Part of Infections clinical trials.
This study looks at how drug resistance mutations in HIV might affect how well certain treatments work, including two-drug regimens. It aims to help doctors choose the best medicines for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be diagnosed with HIV-1.
- You must have had an HIV genotype test (a special lab test) before starting or changing your HIV medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain HIV drug resistance mutations affect how well your immune system recovers after starting HIV treatment. You may qualify if you are newly diagnosed, have never taken HIV meds before, and have a drug resistance test result available.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.